Affordable early detection test for canine lymphoma to hit the market

IDEXX Laboratories shared earlier this month the launch of IDEXX Cancer Dx, a diagnostic panel with early detection of lymphoma in canine patients. The new panel is an accessible blood test that can be added to the panels of sick pets and can be integrated into annual wellness screenings. IDEXX Cancer Dx costs as low as $15, providing professionals in the United States with actionable results within 2 to 3 days.

"Building on over 40 years of IDEXX's leadership in veterinary research and technology development, IDEXX Cancer Dx is our latest groundbreaking solution to deliver unmatched diagnostic insights," said Jay Mazelsky, president and chief executive officer of IDEXX, in an organizational release.¹ "As leaders in key cancer diagnostic categories, like pathology and imaging, we continue to innovate technologies that can redefine how veterinarians approach cancer detection and monitoring in pets. We're proud to be at the forefront of early cancer detection in dogs and look forward to expanding IDEXX Cancer Dx to cover other cancer types."

Image courtesy of IDEXX Laboratories

The IDEXX Cancer Dx panel features¹:

• Actionable next steps: The panel delivers qualitative results for lymphoma, and B-cell and T-cell phenotype classification will be provided positive results as available for no additional cost.
• Accuracy: The IDEXX Cancer Dx has high sensitivity and specific yield results to be used with confidence for both sick and in routine preventative care for at risk canine patients.
• Deeper insights: The panel includes the most comprehensive portfolio of products and services supporting veterinary professionals with preventative care, IDEXX Cancer Dx, unlocks additional insights for at-risk canine patients.
• Personalized guidance and comprehensive support: results come with access to IDEXX Medical Consultants, which includes board certified oncologists and internists as well as educational materials for pet owners and resources to support client communication.
• Simplicity: IDEXX cancer Dx is designed to fit into already existing workflows and diagnostic wellness panels, using a single blood sample.

Cancer is currently the leading cause of death in canine patients with 1 in 4 dogs expected to be diagnosed with cancer in their lifetime, with lymphoma being one of the most common cancers in dogs.^2,3 If detected early, treatments for canine lymphoma can help expand the lifespan of dogs, and improve their quality of life. According to the release, IDEXX Cancer Dx panel can provide a clinical diagnosis of canine lymphoma earlier than traditional diagnostics.¹

"IDEXX Cancer Dx is a powerful innovation in oncology diagnostics," explained Timothy Fan, DVM, PhD, DACVIM (Oncology, Small Animal Internal Medicine). "At an affordable price point, this test increases access to cancer diagnoses and care, and it enables veterinarians the opportunity to intervene sooner and improve the quality of life for canine cancer patients."

IDEXX Cancer Dx testing with canine lymphoma will be available in the United States and Canada in late March 2025 and professionals can learn more in the IDEXX Cancer Dx testing website.

Reference

1. IDEXX Announces Groundbreaking Cancer Dx Panel with Affordable Early Detection Test for Canine Lymphoma. News release. IDEXX Laboratories Inc. January 23, 2025. Accessed January 27, 2025. https://prnmedia.prnewswire.com/news-releases/idexx-announces-groundbreaking-cancer-dx-panel-with-affordable-early-detection-test-for-canine-lymphoma-852823118.html
2. Veterinary Cancer Society. Pet Owner Resources. Veterinary Cancer Society. Accessed January 27, 2025. https://vetcancersociety.org/resources/pet-owners/pet-owner-resources/
3. Vail DM, Thamm DH, Liptak JM. Hematopoietic Tumors. Withrow and MacEwen's Small Animal Clinical Oncology. 2019;688-772. doi:10.1016/B978-0-323-59496-7.00033-5